Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Why Antidepressants Make You Feel Worse Initially GLP 1s: The Second Serving Citrini Research